| Objective To explore the mechanism of Qingxin Zishen decoction in the treatment of perimenopausal syndrome (MPS).Methods The study started from January to June 2021. By searching the TCMSP database, the active ingredients of every drug in Qin?gxin Zishen decoction were acquired. The perimenopausal syndrome disease targets were collected from databases like GeneCards and so on; the predictive target of Qingxin Zishen decoction for treating MPS was obtained after the intersection of the two. A "drug-compo?nent-target-disease" network and a protein interaction network (PPI) were constructed, and then the core network was streamlined. Go enrichment analysis and KEGG pathway enrichment analysis of Qingxin Zishen decoction in the treatment of MPS were carried out by R software.Results 69 main active ingredients were screened, including Luteolin, Quercetin, Stigmasterol, Beta-sitosterol, Kaempfer?ol, Tetrahydroalstonine etc.; 54 gene targets were screened, the core target genes included IL-6, IL-1β, ESR1, SERPINE1, PPARG,CRP, CCND1, PGR, HMOX1, VCAM-1, CYP19A1, IGFBP3, etc.; GO enrichment items were obtained, including the 1 180 Biological Process (BP), 39 Cellular Component (CC), 61 Molecular Function (MF). There were 162 KEGG pathways, including AGE-RAGE sig?naling pathway in diabetic complications, lipid and atherosclerosis signaling pathway, PI3K-Akt signaling pathway, fluid shear stress and atherosclerosis pathway.Conclusion Qingxin Zishen decoction acts on key targets like IL-6, IL-1β, ESR1, SERPINE1, PPARG,CRP, CCND1, PGR, HMOX1, VCAM-1, CYP19A1 and IGFBP3 by regulating glycolipid metabolism, antioxidation, and improving the mechanism of estrogen metabolism to treat perimenopausal syndrome. |
